|
Iadademstat Clinical Trials
4 actively recruiting trials across 4 locations
▼ -2 trials since May 2026
Also known as: ORY 1001, ORY-1001, ORY-1001, RO7051790, RG 6016, RG6016 +3 more
Pipeline
Phase 1: 3Phase 1/2: 1
Top Sponsors
- Yale University1
- Oryzon Genomics S.A.1
- OHSU Knight Cancer Institute1
- National Cancer Institute (NCI)1
Indications
- Cancer4
- Lung Cancer2
- Acute Myeloid Leukemia, in Relapse1
- Extensive Stage Lung Small Cell Carcinoma1
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
Gilbert, Arizona1 trial
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Banner MD Anderson Cancer Center
Phase 1
Duarte, California1 trial
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
City of Hope Comprehensive Cancer Center
Phase 1/2
New Haven, Connecticut1 trial
Iadademstat + SBRT With Atezo in ES-SCLC
Yale University
Phase 1
Portland, Oregon1 trial
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.